Applying machine learning to predict real-world individual treatment effects: insights from a virtual patient cohort
暂无分享,去创建一个
Gang Fang | Izabela E. Annis | Jennifer Elston-Lafata | Samuel Cykert | S. Cykert | G. Fang | I. Annis | J. Elston-Lafata
[1] Max Kuhn,et al. Applied Predictive Modeling , 2013 .
[2] Leo Breiman,et al. Classification and Regression Trees , 1984 .
[3] I. Kohane,et al. Big Data and Machine Learning in Health Care. , 2018, JAMA.
[4] K. Borgwardt,et al. Machine Learning in Medicine , 2015, Mach. Learn. under Resour. Constraints Vol. 3.
[5] Albert T. Young,et al. Development and Validation of an Electronic Health Record–Based Machine Learning Model to Estimate Delirium Risk in Newly Hospitalized Patients Without Known Cognitive Impairment , 2018, JAMA network open.
[6] Tianqi Chen,et al. XGBoost: A Scalable Tree Boosting System , 2016, KDD.
[7] H. Cramér. Mathematical Methods of Statistics (PMS-9), Volume 9 , 1946 .
[8] Ziad Obermeyer,et al. Development and Application of a Machine Learning Approach to Assess Short-term Mortality Risk Among Patients With Cancer Starting Chemotherapy , 2018, JAMA network open.
[9] Euan A Ashley,et al. The precision medicine initiative: a new national effort. , 2015, JAMA.
[10] J. Friedman. Greedy function approximation: A gradient boosting machine. , 2001 .
[11] Leo Breiman,et al. Random Forests , 2001, Machine Learning.
[12] T. Fahey. Applying the results of clinical trials to patients to general practice: perceived problems, strengths, assumptions, and challenges for the future. , 1998, The British journal of general practice : the journal of the Royal College of General Practitioners.
[13] Gang Fang,et al. Practice of Epidemiology Apples and Oranges? Interpretations of Risk Adjustment and Instrumental Variable Estimates of Intended Treatment Effects Using Observational Data , 2011 .
[14] Jennifer G. Robinson,et al. Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin‐Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction , 2018, Pharmacotherapy.
[15] J. Brooks,et al. Interpreting treatment-effect estimates with heterogeneity and choice: simulation model results. , 2009, Clinical therapeutics.
[16] D. Rubin. Estimating causal effects of treatments in randomized and nonrandomized studies. , 1974 .
[17] Olatz Arbelaitz,et al. Applying Resampling Methods for Imbalanced Datasets to Not So Imbalanced Datasets , 2013, CAEPIA.
[18] David M. W. Powers,et al. Evaluation: from precision, recall and F-measure to ROC, informedness, markedness and correlation , 2011, ArXiv.
[19] Annette M. Molinaro,et al. Prediction error estimation: a comparison of resampling methods , 2005, Bioinform..
[20] John Shawe-Taylor,et al. Proceedings of the Sixteenth International Conference on Machine Learning (ICML99) , 1999 .
[21] Richard L Kravitz,et al. Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. , 2004, The Milbank quarterly.
[22] Kai Ming Ting,et al. An Instance-weighting Method to Induce Cost-sensitive Trees , 2001 .
[23] J A Swets,et al. Measuring the accuracy of diagnostic systems. , 1988, Science.
[24] M. Brookhart,et al. Effectiveness and Safety of Dabigatran and Warfarin in Real‐World US Patients With Non‐Valvular Atrial Fibrillation: A Retrospective Cohort Study , 2015, Journal of the American Heart Association.
[25] James J. Heckman,et al. 1. The Scientific Model of Causality , 2005 .
[26] Ewout W Steyerberg,et al. Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests , 2016, British Medical Journal.
[27] William H Crown,et al. Potential application of machine learning in health outcomes research and some statistical cautions. , 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[28] Jennifer G. Robinson,et al. Changes in Statin Adherence Following an Acute Myocardial Infarction Among Older Adults: Patient Predictors and the Association With Follow‐Up With Primary Care Providers and/or Cardiologists , 2017, Journal of the American Heart Association.
[29] M. Zarbin. Challenges in Applying the Results of Clinical Trials to Clinical Practice. , 2016, JAMA ophthalmology.
[30] David M Kent,et al. Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. , 2007, JAMA.
[31] Donald Rubin,et al. Estimating Causal Effects from Large Data Sets Using Propensity Scores , 1997, Annals of Internal Medicine.
[32] Z. Obermeyer,et al. Predicting the Future - Big Data, Machine Learning, and Clinical Medicine. , 2016, The New England journal of medicine.
[33] D. Rubin,et al. The central role of the propensity score in observational studies for causal effects , 1983 .
[34] J. Lunceford,et al. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study , 2004, Statistics in medicine.
[35] Jennifer G. Robinson,et al. Adherence Tradeoff to Multiple Preventive Therapies and All-Cause Mortality After Acute Myocardial Infarction. , 2017, Journal of the American College of Cardiology.
[36] Pierre Geurts,et al. Extremely randomized trees , 2006, Machine Learning.
[37] Alison M Darcy,et al. Machine Learning and the Profession of Medicine. , 2016, JAMA.
[38] Yang Wang,et al. Cost-sensitive boosting for classification of imbalanced data , 2007, Pattern Recognit..
[39] Andrew K. C. Wong,et al. Classification of Imbalanced Data: a Review , 2009, Int. J. Pattern Recognit. Artif. Intell..
[40] Douglas M. Hawkins,et al. Assessing Model Fit by Cross-Validation , 2003, J. Chem. Inf. Comput. Sci..
[41] P. Rothwell,et al. Can overall results of clinical trials be applied to all patients? , 1995, The Lancet.
[42] F. Collins,et al. A new initiative on precision medicine. , 2015, The New England journal of medicine.